Report: A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry TOC

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Stretched to the Breaking Point
Clear and Present Dangers to Biotech and Pharma
- Biotech' s Depleting Cash Reserves and Demands for Cash-Outs
  - Liquidation
  - Layoffs
  - Cash-Outs
- Pharma' s Changing Sources of Growth
- Specter of Comparative Effectiveness
- Threat of Biosimilars
Biotech' s Dream of the Past Three Decades Has Eroded
Staying Alive - Biotech' s Short-Term Imperative
- Life-Saving Cash Injections
  - RDOs and PIPES
  - Corporate Venture Funds
- Life Blood from Collaborations
- Virtualization
- Hibernation
- Consolidation
Big Pharma Turns to Other Big Pharma for Strength
- Recent Collaborations Between Big Pharma
- GlaxoSmithKline Collaborates with Pfi zer on HIV
  - Joint-Venture Strategies
  - Gilead' s Strategies
  - Takeover Possibilities
  - Future Merger?
  - Trend?
Emerging-Markets Lifeline
- Emerging Markets
- Combined Brand and Generics Push
- No Overnight Miracles
Mid-Tier Pharma - The Law of Unintended Consequences
- Mega-Mergers
- Eli Lilly: I Am Biotech
- Bayer Schering: Don' t Put All Your Eggs in One Basket
- Takeda Pharmaceutical: A Balanced Global Presence
Strategies for Moving Forward
On the Horizon - A More Unifi ed Biopharmaceutical Industry

1. Biotechs Out of Business, 2009
2. Biotech Job Losses, January Through June 2009
3. Several Biotech Financings, First Half of 2009
4. Select Pharma-Biotech Collaborations, First Half of 2009
5. Select Biotech-Biotech Collaborations, First Half of 2009
6. Select Mergers and Acquisitions of Biotech Companies, 2008 and 2009
7. Collaborations Between Big Pharma
8. HIV Drug Portfolios: Pfi zer and GlaxoSmithKline Compared with Gilead Sciences
9. Gilead Sciences' Drug Development Pipeline, July 2009
10. Top 20 Worldwide Pharmaceutical Markets, 2003, 2008, and 2013
11. Companies That Disappeared After a Merger

A Global Recession Drives New Business Strategies and Evolving Business Models in the Biopharma Industry